Pharma & Biotech Global Week in Review 13 April 2011 from IP Think Tank

Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Highlights this week included:

Cosopt (Dorzolamide, Timolol) – UK: EWCA (Civ) rejects bid to revive patent covering Cosopt: Merck v Teva (IPKat) (The IP Factor) (EPLAW) (GenericsWeb)

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.


Open Access database of key HIV patents launched by medicines patent pool (IP Watch)

Information challenges for product, process development and process design: a reality check (profitability through simplicity)

‘The price of innovation’: Report suggests that the cost of drug R&D is inflated (IP Osgoode)

Preparing the world for influenza pandemic, industry role key, says WHO (IP Watch)

Australia: Budget cuts threaten Australian medical research funding (Patentology)

Brazil: INPI receives a Denomination of Origin application for Manguezais de Alagoas for propolis (IP tango)

Brazil: Specialized Federal Regional Court upholds action for rescission brought by INPI to overturn extension of two of Monsanto’s patents relating to Roundup (IP tango)

EU: Stem-cell patent debate nearly over after 20 years (IP Osgoode)

EU: Patent linkage? Infringement proceedings by the European Commission against Italy (Kluwer Patent Blog)

India approves free access to important portions of the Traditional Knowledge Digital Library (TK Community) (Spicy IP)

USPTO proposes changes to PTA and PTE provisions (Patent Docs)

US: FDA issues warning letter for failure to submit animal study reports in an IDE (FDA Law Blog)

US: AMP v USPTO – oral argument at the Federal Circuit (Patent Docs)

US: A historical perspective on the gene patent controversy (Holman’s Biotech IP Blog)

US: Novartis files for PTA correction for patent entitled ‘IL-17 antagonist antibodies’ (Patent Docs)

US: Life Technologies file for review of BPAI decision awarding priority to Pacific Biosciences (Patent Docs)

US: District Court E D Texas Judge Ward grants motion to dismiss with leave to replead in false marking case, citing In re BP Lubricants: Promote Innovation v Pfizer (


Amrix (Cyclobenzaprine) – US: Cephalon wins order in patent suit delaying sales of generic form of Amrix (GenericsWeb)

Antara (Fenofibrate) – US: Lupin files patent infringement suit against Ranbaxy following Para IV certification (Patent Docs)

Atorvastatin – Spain: Court of Appeal Barcelona reverses lower court decision which rejected patent owners’ lis pendens defence against revocation action (Kluwer Patent Blog)

Cosopt (Dorzolamide, Timolol) – UK: EWCA (Civ) rejects bid to revive patent covering Cosopt: Merck v Teva (IPKat) (The IP Factor) (EPLAW) (GenericsWeb)

Cubicin (Daptomycin) – US: Cubist and Teva resolve dispute (IP Factor)

Dexilant (Dexlansoprazole) – US: Takeda Pharmaceutical files patent infringement suit against Dr Reddy’s following Para IV certification (Patent Docs) (GenericsWeb)

Doryx (Doxycycline) – US: Simultaneously qualifying for and forfeiting 180-day exclusivity eligibility for failure to obtain timely tentative approval (FDA Law Blog)

Eloxatin (Oxaliplatin) – US: CAFC: Confidentiality designations in Federal Circuit appeals: In re violation of Rule 28(D) (Patently-O)

Escitalopram – Austria: Supreme Court rules SPC valid: Lundbeck v Ratiopharm (EPLAW)

Fabry (Fabryzyme) – US: Fabry patients request rehearing of NIH march-in request for Genzyme’s Fabrazyme patents (Patent Docs)

Focalin (Dexmethylphenidate) – US: Elan files patent infringement suit against Mylan in response to Para IV certification filing (Patent Docs)

Galantamine – EU: AG delivers opinion on SPC questions in Generics v Synaptech (EPLAW)

Memantine – EU: AG delivers opinion on SPC questions in Synthon v Merz (EPLAW)

OxyContin (Oxycodone) – US: Impax challenges Oxycontin patents, faces lawsuit (GenericsWeb)

Valsacor (Valsartan) – Slovenia: Higher Court Ljubljana rejects interim injunction request because alleged infringer did not use claimed method (Kluwer Patent Blog)

Vigamox (Moxifloxacin) – US: Watson confirms Vigamox patent challenge (GenericsWeb)

Zyprexa (Olanzapine) – US: Eli Lilly files patent infringement complaint against Accord Healthcare in response to Para IV challenge (Patent Docs)

%d bloggers like this: